Study of MG-K10 for chronic hives
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medication called MG-K10 for people with chronic spontaneous urticaria (chronic hives) that hasn't improved with standard antihistamines. The goal is to see if MG-K10 can reduce itching and hives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic hives for at least 6 months.
- Your hives and itching continue even with antihistamine treatment.
- Your symptoms are moderate to severe based on a scoring system.
- You agree to use effective birth control during the study and for 6 months after the last dose.
- You have not used certain other treatments or have other skin conditions that might interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called MG-K10 for people with chronic hives (itchy welts) that don't go away with standard antihistamines. It aims to see if the drug can reduce itching and hives, possibly offering another treatment option.
This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.
This trial tests a new injection (CM512) for people with chronic spontaneous urticaria, also known as chronic hives. If you have had itchy hives for at least 6 weeks despite taking regular antihistamines, this study may help find a new treatment option.
This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.
This trial tests a new medicine, JYB1904, for people with chronic hives (itching and welts) that haven't been controlled by standard allergy pills. It aims to see if JYB1904 can reduce itching and hives better.
This trial tests a new oral medication for chronic spontaneous urticaria (chronic hives). It is a placebo-controlled study, meaning some participants will get the new drug and some will get a placebo (a pill with no active ingredient). The goal is to see if the new drug is safe and how well it works, possibly providing a new treatment option for those whose hives are not controlled by current antihistamines.
Hear when a new Chronic Urticaria, Idiopathic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.